A close up of a researcher extracting a solution from a petri dish.
Our Work

Latham & Watkins Advises Parvus Therapeutics on Collaboration With AbbVie

March 29, 2024
Firm advises the preclinical-stage company on licensing collaboration and option agreement for Inflammatory Bowel Disease therapies.

Parvus Therapeutics has announced that it has entered into an exclusive worldwide license collaboration and option agreement with AbbVie Inc. (NYSE: ABBV) for the development and commercialization of novel treatments for Inflammatory Bowel Disease (IBD), utilizing Parvus’ Navacim™ Treg immune tolerization platform technology. Navacims™ present multivalent peptide major histocompatibility complexes (peptide-MHCs) to T cells, triggering the endogenous expansion and differentiation of the T cells into antigen-specific Tregs. This approach is being evaluated as a potential to halt or cure autoimmune disease by restoring organ-specific immune tolerance without compromising normal immunity.

Latham & Watkins advised Parvus on the agreement, with a team led by Bay Area partner Judith Hasko, with associates Robert Yeh and Xiaohan (Billy) Wu. Advice was also provided on corporate matters by Bay Area partner Ben Potter; on FDA matters by Washington, D.C. partner Elizabeth Richards; on tax matters by Bay Area partner Kirt Switzer, with associate Greg Conyers; on data privacy matters by Bay Area partner Heather Deixler, with associate Oliver Mobasser; on antitrust matters by Washington, D.C. partner Peter Todaro; and on anti-corruption and compliance matters by New York partner Matthew Salerno.